Alcohol-associated hepatitis (AH) accounted for an increasing proportion of alcohol-associated liver disease (ALD) liver transplant listings in the United States between 2014 and 2024, according to a retrospective registry analysis presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting.¹ Among patients selected for waitlisting, those with AH had higher liver disease severity scores at listing but were more likely to undergo transplantation than candidates with other forms of ALD.
Leandro Sierra, MD, an internal medicine resident at Cleveland Clinic, presented the analysis, which received an ACG Presidential Poster Award, in Nashville, Tennessee. In an interview with HCPLive, Sierra discussed the increasing proportion of AH listings, differences in transplant access across centers, and opportunities for further research.
Severe Alcohol-Associated Hepatitis and Transplant Candidacy
AH is an acute inflammatory manifestation of ALD, often occurring in patients with underlying chronic liver disease. Severe AH is associated with substantial short-term mortality, particularly among patients who do not respond to medical treatment.
The 2024 ACG clinical guideline identifies severe AH using a Model for End-Stage Liver Disease (MELD) score greater than 20 and supports consideration of early liver transplantation in carefully selected patients who do not respond to medical management.²
Historically, liver transplantation for AH was limited by selection practices, including requirements for a predetermined period of alcohol abstinence. Contemporary guidance emphasizes individualized assessment rather than relying exclusively on a fixed abstinence period.²
Sierra noted that these patients historically were not listed for transplant, and many died without that option.
AH Listings Increased From 0.9% to 16.3%
Investigators analyzed United Network for Organ Sharing (UNOS) registry data involving 82,014 steatotic liver disease transplant candidates listed between 2014 and 2024.¹ ALD accounted for 39.0% of the overall cohort, overtaking metabolic dysfunction-associated steatotic liver disease (MASLD) as the leading subtype, as [HCPLive previously reported](ARTICLE 1 LINK).
Within the ALD population, the proportion of listings involving AH increased from 0.9% to 16.3% over the study period.¹
The odds of an ALD registrant having AH increased annually (odds ratio [OR], 1.34), while AH listings demonstrated a greater annual rate of increase relative to other ALD listings (incidence rate ratio [IRR], 1.31).¹
These findings describe changes in the composition of the transplant waitlist and do not necessarily reflect changes in AH incidence in the general population.
Patients With AH Were More Likely to Receive Transplants
Patients with AH had higher MELD scores at listing than candidates with other forms of ALD, suggesting greater liver disease severity at the time of waitlisting.¹
Despite this difference, 78.3% of listed AH candidates underwent liver transplantation, compared with 64.1% of candidates with other forms of ALD. An additional 7.1% of AH candidates were removed from the waitlist following clinical improvement.¹
Because listed AH candidates are a selected group, these transplant rates may not reflect outcomes among all patients with severe AH.
Sierra highlighted variation in transplant listing practices across centers and the potential relevance of the findings for clinicians evaluating patients with severe AH.
“There are multiple centers that still are not listing patients with alcohol-associated hepatitis for liver transplant,” Sierra said. “Maybe they can take away from this study how other centers have been doing it, how the rest of the country has been doing it.”
Earlier Intervention and Future Research in ALD
Beyond changes in AH waitlisting, Sierra identified several priorities for future research, including earlier intervention in ALD, geographic differences in disease burden, and further evaluation of transplant candidacy among patients with severe AH.
He also discussed the potential role of glucagon-like peptide-1 (GLP-1) receptor agonists earlier in the course of ALD.
Although GLP-1 receptor agonists have established roles in treating several metabolic conditions, their potential use for alcohol-related outcomes remains an area of investigation. The registry analysis did not assess GLP-1 receptor agonist exposure or treatment effects.
Sierra suggested future studies could examine whether these agents have a role before patients progress to liver transplant evaluation.
Editor’s Note: Sierra reported no relevant disclosures.
References
Sierra L, Gakhoury B, Parraga X, et al. The Rise of Alcohol-Associated Liver Disease as the Leading Indication for Liver Transplant Waitlisting Among Patients With Steatotic Liver Disease. Poster presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN. Poster P3946.
Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024;119(1):30-54. doi:10.14309/ajg.0000000000002572